MRSA Dx Sales Help Drive 37 Percent Jump in Cepheid's Q2 Revenues | GenomeWeb
NEW YORK (GenomeWeb News) — Cepheid today said second-quarter revenues increased 37 percent as R&D spending rose 28 percent and net loss declined around 26 percent.
Total receipts for the three months ended June 30 increased to $27.2 million from $19.8 million year over year. This included $23.6 million of total product sales, which increased 25 percent to from $18.9 million for the second quarter 2006.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.